Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 81.98B |
| Revenue (ttm) | 13.85B |
| Net Income (ttm) | 4.65B |
| Shares Out | 107.59M |
| EPS (ttm) | 40.43 |
| PE Ratio | 18.85 |
| Forward PE | 16.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,027,665 |
| Open | 753.95 |
| Previous Close | 756.81 |
| Day's Range | 750.20 - 762.70 |
| 52-Week Range | 750.20 - 1,211.20 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 1,110.63 (+45.75%) |
| Earnings Date | Oct 31, 2024 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, Regeneron Pharmaceuticals's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1,110.63, which is an increase of 45.75% from the latest price.
News
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
The Investment Committee give you their top stocks to watch for the second half.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih...
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regeneron Pharmac...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron shares fell 9.2% after the Q3 2024 report, making the company's valuation more attractive. The strong report was the 15th of 16 in the last four years to beat expectations. Investors were sp...
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors conce...
Regeneron: Investors In Panic Mode On Increased Eylea Fears
Shares of Regeneron are in free fall after recent litigation setbacks on Eylea and with Amgen launching a biosimilar low-dose version of Eylea. Investors may be overestimating the negative impact of t...
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board C...
Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye dise...
Regeneron Reports Third Quarter 2024 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if a...
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wel...
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the ...
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time...
Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)
Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to musc...
Stock Picks From Seeking Alpha's September 2024 New Analysts
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administrati...
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary d...
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Fr...